Focus: Inpharmus is a Turkish biotechnology company founded in 2013 that markets approved small molecules and biologics across neurology, infectious diseases, immunology, cardiovascular, and respiratory indications. The company operates as a specialty pharma player with a heavily commercialized portfolio rather than an R&D-driven pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Inpharmus to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Inpharmus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Inpharmus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship asset representing 71% of company revenue; peak lifecycle status with 9+ years of LOE protection provides revenue certainty but dependency risk.
Second-largest revenue contributor facing patent cliff in January 2028, creating $50M revenue erosion risk without pipeline replacement.
Biologic monoclonal antibody with peak lifecycle status and indefinite patent protection, representing strategic diversification from small molecules.
Small but profitable biologic asset with peak lifecycle and no LOE date, contributing to oncology presence with modest revenue.
89 discontinued, 80 duplicate formulations not shown
No open positions listed yet.
Source: USCIS H-1B Employer Data Hub
+59 more products
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo